Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.

Abstract: Among other things, a method is disclosed comprising: receiving image data representing an image; processing the data to generate orientation information; processing the data using the orientation information to measure a quantity called local phase in a direction perpendicular to the orientation of a putative vessel; using the phase measurements from three collinear image locations or from two locations to detect the centerline of a symmetric image structure, such as a blood vessel, and to locate a center-point defined by the intersection of the centerline with the line created by the measurement locations.

Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Levels of CCL7 have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of CCL7 and/or other members of the PAR1-CCL7 axis, or CCL2 can be used to prevent and/or treat these conditions.

Abstract: Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided.

Abstract: A method of measuring surface curvature comprises forming an intensity distribution defined by Fresnel diffraction, wherein said intensity distribution is formed by electromagnetic radiation reflected from a surface, obtaining data for the intensity distribution and determining information relating to the curvature of the surface using the obtained data.

Abstract: The present invention relates to methods of isolating pathogenic genomes from a clinical sample.

Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.

Abstract: Lentiviral packaging cells and methods for producing the same are provided herein. Specifically, lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are provided. Methods for producing lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are described.

Abstract: A method for producing a solution of dispersed graphenes comprising contacting graphite having a dimension in the a-b plane of 10 ?m or less with an electronic liquid comprising a metal and a polar aprotic solvent, and solutions of dispersed graphenes which may be obtained by such a method are described.

Abstract: The invention provides light-emitting compositions, including lasing and fluorescent compositions. The invention particularly relates to programmable biological substrates, which fluoresce and/or lase, and which have a wide variety of different applications. The invention extends to use of the fluorescent compositions and lasing compositions comprising programmable biological substrates in fabricating lasers, and in various biological imaging applications, such as in assays.

Abstract: One embodiment of the invention provides a method and apparatus for performing deep brain stimulation with an electromagnetic field. The includes an electrode assembly having multiple electrodes and a phased array system for driving the electrodes to generate the electromagnetic field. By controlling delays within the phased array system, the generated electromagnetic field can be steered to a desired region of the brain.

Abstract: The invention relates to the derivation of mesoangioblast-like (MAB-like) cells from pluripotent cells such as induced pluripotent (IPS) and embryonic stem (ES) cells, to cells obtained thereby and to medical uses of such cells, in particular in the treatment of muscular dystrophies.

Abstract: A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R1 and R1* represents hydrogen and the other represents methyl, R2 represents ethyl or isopropyl, R3 represents hydrogen or methyl, and R4 represents —CH2CH(CH3)CH3, —CH2CH(CH3)CH2CH3, —CH(CH3)CH3 or —CH(CH3)CH2CH3.

Abstract: The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease. The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

Abstract: The present invention provides a method for the detection of particulates in a sample, wherein the particulates are introduced into a plasma and the potential difference between a common electrode and each of a plurality of indicator electrodes is measured. The invention further provides an electrode array and an apparatus which can be used for the potentiometric detection of particulates in a sample.

Abstract: The present invention relates to a hydrogen, methanol, or ethanol fuel cell comprising an anode electrocatalyst comprising palladium and iridium, and relates to a fuel cell stack comprising said fuel cell. The invention also relates to a method of making a fuel cell. The invention also relates to the use of the anode electrocatalyst in a hydrogen, methanol or ethanol fuel cell.

Abstract: The invention relates to a membrane for supporting cells, especially retinal pigmented epithelial (RPE) cells. The membrane is useful in the treatment of conditions such as age related macular degeneration. The membrane may also be used to support retinal pigmented epithelial cell precursors and retinal cell derivative cells formed from the differentiation of RPE on the membrane.

Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.

Abstract: A method for removing impurities from a sample of carbon nanotubes wherein the sample is contacted with an electronic liquid comprising a metal and an amine solvent is described.

Abstract: A magnetic resonance imaging (MRI) method of investigating tissue fluid velocity in a region of interest comprising substantially eliminating the magnetic resonance signal of blood flowing in one or more blood vessels in the tissue by applying a nulling preparation to the tissue; and deriving the interstitial fluid velocity using magnetic field gradients.